Early buyers will receive 10% customization on this report.
The growing use of polymers is expected to lower the price of microfluidic products. This, in turn, will increase the adoption of microfluidic technologies, and thereby support the growth of the market during the forecast period. In addition to this, growing investments, favorable regulatory policies, and growth in healthcare and biotechnology industries in emerging Asian markets are expected to provide potential growth opportunities for players operating in the microfluidics market.
Furthermore, growing application of microfluidic technology in personalized medicine, organ-on-a-chip, and liquid biopsies; expanding application of microfluidics in drug delivery systems such as insulin pumps and inhalers is further expected to drive the market during the forecast period.
By application, the in vitro diagnostic segment accounted for the largest share of the microfluidics market in 2017
On the basis of application, the microfluidics market is broadly segmented into in vitro diagnostics, pharmaceutical and lifescience research, drug delivery, and laboratory testing. In 2017, the in vitro diagnostics segment accounted for the largest share of this market.
Microfluidic technologies are used in in vitro diagnostics for clinical diagnostics and POC testing. Rising incidence of chronic diseases, aging population, increasing healthcare spending in emerging countries, growing demand for point-of-care testing, and rapid technological changes in molecular diagnostics are some of the major factors supporting the growth of the microfluidics market for IVD applications during the forecast period.
IVD embedded with microfluidic technologies such as POC diagnostics, PCR systems, analyzers, and electrophoretic systems are increasingly being used in diagnostics, agriculture, forensics, water testing, and environmental screening. These devices provide various advantages such as portability due to reduced size of the device, increased frequency of testing and accurate & quick analysis.
By type, microfluidic chips segment accounted for the largest share of the microfluidics components market in 2017
Based on the type, the microfluidic components market is further segmented into microfluidic chips, microfluidic sensors, micropumps, microneedles, and others. In 2017, microfluidic chips segment accounted for the largest share of this market. Factors such as the growing demand for point-of-care testing, increasing use of personalized medicine for the treatment of various chronic diseases, rising number of drug discovery and life sciences research activities, growing need for high-speed diagnostics, and increased government funding are attributed to the large share of the microfluidic chips market.
North America dominated the market in 2017
North America accounted for the largest share of the microfluidics market in 2017, followed by Europe and Asia Pacific. The largest share of the North American region is mainly attributed to the higher incidence rate of chronic diseases, availability of insurance coverage for laboratory testing procedures, sufficient reimbursements for medical devices, and presence of well-structured distribution channels in the region.
In addition, high demand for self-administration and home healthcare devices, and increasing applications of micropumps, inhalers, and transdermal microneedles for chronic conditions such as migraine, diabetes, cancer pain, and asthma have further resulted in the large share of this market.
The key players in the global microfluidics market are Danaher (US), Thermo Fisher (US), PerkinElmer (US), Agilent (US), Bio-Rad (US), Becton, Dickinson and Company (US), Roche (Switzerland), Illumina (US), Fluidigm Microfluidics (US), and QIAGEN (Netherlands). Other key players include Dolomite Microfluidics (UK), GYROS PROTEIN TECHNOLOGIES AB (Sweden), Sphere Fluidics (UK), OPKO Health (US), Waters (US), thinXXS Microtechnology (Germany), Abaxis (US), BioMérieux (France), Abbott (US), Dolomite Microfluidics (UK), Microfluidic ChipShop (Germany), Elveflow (France), Cellix (Ireland), Micronit Microtechnologies (Netherlands), MicroLiquid (Spain), MiniFAB (Australia), uFluidix (Canada), Micralyne (US), and Fluigent (France).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
